Updated Experience of
Mycobacterium chimaera
cardiovascular surgery
nontuberculous mycobacterium
prosthetic valve endocarditis
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
13
05
2021
accepted:
29
06
2021
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
12
8
2021
Statut:
epublish
Résumé
Despite safety communications from the Food and Drug Administration (FDA) regarding the outbreak of We retrospectively reviewed confirmed cases of MCI that were managed at Mayo Clinic sites (Arizona, Florida, and Minnesota) from 09/2015 to 01/2021. Clinical histories including prior cardiovascular surgery were recorded. Diagnostic workup including ophthalmologic examination, imaging, and laboratory testing was reviewed. Treatment and survival outcomes on follow-up were obtained. Twelve patients with MCI were included. All patients had aortic valve or graft replacement. Five patients had their surgical procedures following the 10/15/2015 FDA safety communication. The mean time from surgery to symptom onset (range) was 32 (13-73) months. Ten of 11 patients who underwent ophthalmologic examination had chorioretinal abnormalities. Three patients who underwent microbial cell-free deoxyribonucleic acid sequencing tested positive for MCI continues to occur despite the FDA communications. Incorporation of ophthalmologic examination and use of advanced tools may improve MCI diagnosis. The mortality in these patients is high even with aggressive surgical/medical management.
Sections du résumé
BACKGROUND
BACKGROUND
Despite safety communications from the Food and Drug Administration (FDA) regarding the outbreak of
METHODS
METHODS
We retrospectively reviewed confirmed cases of MCI that were managed at Mayo Clinic sites (Arizona, Florida, and Minnesota) from 09/2015 to 01/2021. Clinical histories including prior cardiovascular surgery were recorded. Diagnostic workup including ophthalmologic examination, imaging, and laboratory testing was reviewed. Treatment and survival outcomes on follow-up were obtained.
RESULTS
RESULTS
Twelve patients with MCI were included. All patients had aortic valve or graft replacement. Five patients had their surgical procedures following the 10/15/2015 FDA safety communication. The mean time from surgery to symptom onset (range) was 32 (13-73) months. Ten of 11 patients who underwent ophthalmologic examination had chorioretinal abnormalities. Three patients who underwent microbial cell-free deoxyribonucleic acid sequencing tested positive for
CONCLUSIONS
CONCLUSIONS
MCI continues to occur despite the FDA communications. Incorporation of ophthalmologic examination and use of advanced tools may improve MCI diagnosis. The mortality in these patients is high even with aggressive surgical/medical management.
Identifiants
pubmed: 34377729
doi: 10.1093/ofid/ofab348
pii: ofab348
pmc: PMC8339283
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab348Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
J Clin Microbiol. 2013 Jun;51(6):1769-73
pubmed: 23536407
Nat Microbiol. 2019 Apr;4(4):663-674
pubmed: 30742071
J Infect. 2020 Feb;80(2):197-203
pubmed: 31863789
J Thorac Cardiovasc Surg. 2017 Jun;153(6):1422-1424.e1
pubmed: 28351477
Eur Heart J. 2015 Oct 21;36(40):2745-53
pubmed: 26188001
Infect Control Hosp Epidemiol. 2017 Jan;38(1):103-108
pubmed: 27839530
Clin Infect Dis. 2015 Jul 1;61(1):67-75
pubmed: 25761866
Lancet Infect Dis. 2017 Oct;17(10):1033-1041
pubmed: 28711585
J Hosp Infect. 2020 Feb;104(2):214-235
pubmed: 31715282
Circulation. 2015 Oct 13;132(15):1435-86
pubmed: 26373316
J Nucl Cardiol. 2019 Jun;26(3):922-935
pubmed: 29086386
Open Forum Infect Dis. 2016 Jun 16;3(3):ofw131
pubmed: 27703994
Ophthalmology. 2017 Feb;124(2):178-188
pubmed: 27871762
Clin Microbiol Infect. 2018 Nov;24(11):1164-1170
pubmed: 29803845
Front Microbiol. 2021 Jan 11;11:586657
pubmed: 33505365
J Hosp Infect. 2016 Jul;93(3):223-8
pubmed: 27101883
Emerg Infect Dis. 2016 Jun;22(6):1008-13
pubmed: 27070958
Clin Infect Dis. 2020 Feb 3;70(4):583-594
pubmed: 30949690
Emerg Infect Dis. 2018 Mar;24(3):576-578
pubmed: 29460746